Sofiniclin (ABT 894), an agonist of nicotinic acetylcholine receptor (nAChR) , is used as a potential non-stimulant research for attention-deficit/hyperactivity disorder (ADHD). In Vitro Sofiniclin is more potent than ABT-089 at both receptor subtypes, with K i values of 1.9 nM for 125 I-α-conotoxinMII binding and of 1.3 nM for 125 I-epibatidine binding. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo Sofiniclin (0.001 to 0.10 mg/kg, p.o.) produces significant reductions in LIDs compared to vehicle monkey . Sofiniclin (0.1 mg/kg) does not decrease LIDs in monkeys with severe nigrostriatal damage. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid